Skorzewiak / Shutterstock.com
15 April 2025NewsPharmaLiz Hockley

Fed Circ decides fate of Orange Book patent covering blockbuster J&J schizophrenia drug

Court hears arguments from J&J and Teva to determine whether a patent blocking generic versions of Invega Sustenna will be upheld | J&J fights to protect its last remaining Orange Book patent covering Invega Sustenna.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Week Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Atif Choudhury at achoudhury@lifesciencesipreview.com 


More on this story

Pharma
11 August 2026   A litigation campaign against generic drugmakers, including Sandoz, Hikma, and Amenal, raise the stakes in the fight over two of the world’s most lucrative weight loss and diabetes treatments.
Pharma
10 August 2026   Takanori Abe of Abe & Partners brings the perspective of a lawyer with first-hand experience in the German courtrooms to Pharmaceutical, Biological and Chemical Patents, a valuable resource on case law.
Pharma
6 August 2026   A Netherlands court ruling marks the latest win as Novo Nordisk ramps up efforts to protect semaglutide from unapproved products, copycats and an increasingly competitive market.